Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Jordan Wolff

Gastroenterology Lutherville, MD Medical Doctor

NPI 1205038197 CMS profile 852715

1447 York Rd Ste 100, Lutherville, MD 21093

Open in the dashboard

General payments

$328

4 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jordan Wolff of Lutherville, MD is reported in the CMS Open Payments database as having received $328 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 20th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $81 1
2022 General $229 2
2021 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Wolff
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jordan Wolff were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jordan Wolff Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $18 $352 $106–$1,054 $132
2022 $229 $448 $129–$1,270 $149
2023 $81 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Boston Scientific Corporation $310 3 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $328 4 payments
Products named General payments · program years 2021–2023
  1. Axios $194 2 payments
  2. General - Hemostasis $116 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,435

Median for Gastroenterology: 569

Drug cost

$575,772

Median for Gastroenterology: $104,976

Branded share of claims

59.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $176,815
Entyvio Pen Vedolizumab Brand 25 $115,568
Rinvoq Upadacitinib Brand 13 $102,846
Creon Lipase/Protease/Amylase Brand 42 $88,489
Mesalamine Generic 96 $26,284
Amjevita(Cf) Autoinjector Adalimumab-Atto Brand 14 $25,975
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 671 $15,035
Ursodiol Generic 22 $4,253
Lubiprostone Generic 36 $3,665
Budesonide Dr Budesonide Brand 30 $3,150

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record